Bank of New York Mellon’s Titan Pharmaceuticals TTNP Stock Holding History

Bank of New York Mellon’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-770	Closed	-$40K	–	4564
2021 Q2	$40K	Sell	770 -140	-15%	-$7K	﹤0.01%	4352
2021 Q1	$54K	Buy	+910	New	+$60.2K	﹤0.01%	4248
2019 Q1	–	Sell	-4	Closed	-$3K	–	4256
2018 Q4	$3K	Hold	4	–	–	﹤0.01%	4220
2018 Q3	$3K	Hold	4	–	–	﹤0.01%	4238
2018 Q2	$14K	Sell	4 -1	-20%	-$3.35K	﹤0.01%	4190
2018 Q1	$17K	Buy	5 +1	+25%	+$4.18K	﹤0.01%	4277
2017 Q4	$18K	Hold	4	–	–	﹤0.01%	4306
2017 Q3	$22K	Hold	4	–	–	﹤0.01%	4208
2017 Q2	$24K	Sell	4 -13	-76%	-$121K	﹤0.01%	4216
2017 Q1	$206K	Hold	17	–	–	﹤0.01%	3874
2016 Q4	$249K	Hold	17	–	–	﹤0.01%	3830
2016 Q3	$359K	Sell	17 -1	-6%	-$19.4K	﹤0.01%	3691
2016 Q2	$347K	Buy	18 +10	+125%	+$213K	﹤0.01%	3689
2016 Q1	$135K	Buy	8 +4	+100%	+$53.4K	﹤0.01%	3901
2015 Q4	$72K	Buy	+4	New	+$65.2K	﹤0.01%	4122

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Trust Company Manhattan, Kansas $1.11B AUM 13.1% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Bank of New York Mellon's TTNP Position: Q3 2021 in Review

Bank of New York Mellon sold out of Titan Pharmaceuticals (TTNP) in Q3 2021, closing a stake of 770 shares — an estimated $40K sold.

Bank of New York Mellon first reported a position in TTNP in Q4 2015 and held it in 15 quarters. The position peaked at $359K in Q3 2016. 12 funds tracked by Wall St. Rank hold TTNP as of Q3 2021.

Bank of New York Mellon reported no remaining Titan Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bank of New York Mellon sold 770 Titan Pharmaceuticals shares in Q3 2021, an estimated $40K.
Bank of New York Mellon first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 15 quarters.
Bank of New York Mellon's Titan Pharmaceuticals position peaked at $359K in Q3 2016.
12 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2021.

Based on Bank of New York Mellon's 13F filing for Q3 2021, filed 12 Nov 2021.